Coherus Oncology, Inc. (CHRS) Profit Margin
Coherus Oncology, Inc. (CHRS) net profit margin by fiscal period. Analyze profit margins in Excel with MarketXLS.
Profit Margin Data
| Period | Net Profit Margin |
|---|---|
| 2016-12-31 | -66.98% |
| 2017-12-31 | -15306.56% |
| 2018-12-31 | N/A |
| 2019-12-31 | 25.23% |
| 2020-12-31 | 27.79% |
| 2021-12-31 | -87.92% |
| 2022-12-31 | -138.24% |
| 2023-12-31 | -92.48% |
| 2024-12-31 | 108.03% |
| 2025-12-31 | 398.43% |
How CHRS compares with sector peers
| Symbol | Company | Net profit margin (latest fiscal year) |
|---|---|---|
| BCRX | BioCryst Pharmaceuticals Inc. | 30.16% |
| BIO | Bio-Rad Laboratories Inc. Class A | 29.42% |
| ARWR | Arrowhead Pharmaceuticals Inc. | -0.20% |
| AZTA | Azenta Inc. | -9.39% |
| ACHV | Achieve Life Sciences Inc. | -24.38% |
These are five companies in the same sector as CHRS with a comparable annual net profit margin. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Coherus Oncology, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Profit_Margin("CHRS", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | CHRS | $1.29 | -2.63% | 0.19M |
| 3 | ||||
| 4 | ||||
| 5 |